Galecto Inc - ESG Rating & Company Profile powered by AI
Other corporations in the scoring peer group for Galecto Inc are displayedin the table. The SDG rating for Galecto Inc indicates the company's transparency towards the United Nations Sustainable Development Goals. Complete Sustainability assessment of Galecto Inc can be reached by signing up for free.
Galecto Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.0; made up of an environmental score of 2.7, social score of 3.2 and governance score of 6.0.
4.0
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 989 | Spectrum Pharmaceuticals Inc | 4.1 | High |
| 989 | Tricida Inc | 4.1 | High |
| 1004 | Galecto Inc | 4.0 | High |
| 1004 | Can B Corp | 4.0 | High |
| 1004 | CLS Holdings USA Inc | 4.0 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Galecto Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Galecto Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Galecto Inc report the average age of the workforce?
Sign up for free to unlockDoes Galecto Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Galecto Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Galecto Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Galecto Inc offer flexible work?
Sign up for free to unlockDoes Galecto Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Galecto Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Galecto Inc conduct supply chain audits?
Sign up for free to unlockDoes Galecto Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Galecto Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Galecto Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Galecto Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Galecto Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Galecto Inc disclose water use targets?
Sign up for free to unlockDoes Galecto Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Galecto Inc have a product recall in the last two years?
Sign up for free to unlockDoes Galecto Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Galecto Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Galecto Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Galecto Inc disclose parental leave metrics?
Sign up for free to unlockDoes Galecto Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Galecto Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Galecto Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Galecto Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Galecto Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Galecto Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Galecto Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Galecto Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Galecto Inc disclose its waste policy?
Sign up for free to unlockDoes Galecto Inc report according to TCFD requirements?
Sign up for free to unlockDoes Galecto Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Galecto Inc disclose energy use targets?
Sign up for free to unlockDoes Galecto Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Galecto Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Galecto Inc
These potential risks are based on the size, segment and geographies of the company.
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.